Zydus Lifesciences is launching a proof-of-concept Phase 2a clinical trial to evaluate the safety and efficacy of its oral candidate desidustat in people with sickle cell disease (SCD). The study is the result of a collaboration with the Indian Council of Medical Research (ICMR). “Public-private partnerships in the…
News
Women with sickle cell disease (SCD) experience significant challenges with healthcare while struggling with both the physical and social toll of the disease, a new study from the University of Pennsylvania reports. Managing physical pain, facing emotional challenges, and feeling stigma from healthcare providers, especially when transitioning from…
Enlargement of the left atrium, one of the heart’s upper chambers, is associated with a greater sickle cell disease (SCD) burden for patients, with more emergency department visits and blood test abnormalities, according to a new study from the U.S. A larger left atrium is believed to be a…
Preschool-aged children with sickle cell disease (SCD) living in so-called food deserts, or areas where access to healthy food is limited, and those without reliable transportation are at a higher risk of experiencing health issues than other youngsters with SCD, even when they receive good medical care, a study…
Mitem Pharma has acquired worldwide rights to Desferal (deferoxamine), a therapy commonly used to lower excessive and damaging iron levels induced by blood transfusions in people with sickle cell disease (SCD) or other anemias. The acquisition was reached in an agreement between Mitem and Novartis, which…
The number of stroke cases among adults and children with sickle cell disease (SCD) continues to increase in at least one U.S. state, indicating a need for greater adherence to standard-of-care blood transfusions and more attention paid to factors that can be controlled to reduce the risk of…
Pfizer has voluntarily withdrawn Oxbryta (voxelotor), a conditionally approved oral therapy for sickle cell disease (SCD), from worldwide markets, saying clinical data shows the treatment’s benefit “no longer outweighs the risk.” Citing an imbalance in vaso-occlusive crises (VOCs) and deaths occurring in patients given Oxbryta in postmarketing…
A Nigerian hematologist will pursue a PhD in health policy at the University of Tennessee Health Science Center to help advance her work on programs for sickle cell disease (SCD) in her home country. Aisha Galadanci Akilu, MD, helped implement a newborn screening program in Kano City, Nigeria, which…
Sigma Gamma Rho Sorority, a national collegiate women’s organization, has committed to raising $2 million by 2028 to support St. Jude Children’s Research Hospital in its efforts to treat children with sickle cell disease (SCD), cancer, and other serious conditions at no cost to their families. The…
People with sickle cell trait (SCT), those who carry a mutation in one copy of the HBB gene but do not have sickle cell disease (SCD), are at an increased risk of blood clots compared with people who don’t carry the trait regardless of racial or ethnic background, according…
Recent Posts
- Sickle cell drug at high dose eases anemia symptoms in severe SCD
- Researchers urge more talk on menstrual pain in sickle cell clinics
- Sickle cell patients shifting to adult care visit ER more often: US study
- Early results of trial testing tebapivat in SCD expected later this year
- Gathering new evidence helps me tackle my fears with sickle cell
- Differences in red blood cell stiffness may explain variations in SCD severity
- Don’t let sickle cell pain crises keep you from setting goals
- FDA awards breakthrough device status to sickle cell diagnostic test
- Blood screen may spot potential complications in sickle cell children
- The good and bad of being a medical doctor and a sickle cell disease patient